Study of a new drug for advanced HER2-positive breast cancer
Part of Cancer, Skin clinical trials.
This study tests a new drug, SMP-656, for people with advanced HER2-positive breast cancer that has stopped responding to previous treatments. The goal is to see if it can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have HER2-positive breast cancer that has spread and cannot be removed by surgery.
- Your cancer has gotten worse after treatment with a certain type of drug like DS-8201 (an antibody-drug conjugate).
- You have at least one tumor that can be measured on scans.
- You are able to care for yourself (ECOG score 0 or 1) and are expected to live at least 3 months.
- Your blood, liver, and kidney function are within normal limits, and you have no serious heart, lung, or other health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two targeted medicines for people with a certain type of advanced breast cancer that has grown despite hormone therapy. The medicines may help shrink tumors and slow the cancer's growth.
This trial tests a new combination of two study drugs (JSKN016 and D-0502) for people with a common type of advanced breast cancer (HR-positive, HER2-negative) that has grown after standard hormonal and CDK4/6 inhibitor treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests an experimental drug called JNJ-101684362 (HLD-0117) for people with metastatic breast cancer that has not responded to other treatments. It may help by targeting cancer cells in a new way, and the study will check if it is safe and effective.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This Phase 1 trial tests a combination of immune-targeting drugs (a CD40 medicine and a substance that helps immune cells act) plus chemotherapy in people with HER2-negative advanced breast cancer that has progressed. It aims to find a safer dose and see whether the treatment can shrink tumors or slow the cancer.
This trial tests a new drug called SMP-3124LP for people with advanced solid tumors that no longer respond to standard treatments. It is given in two phases: first to find the best dose (dose escalation) and then to see how well it works in specific cancer types (dose expansion).
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.